Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
miltefosine + imiquimod
- Development stage
- Phase 2
- Lead developer
- FOUNDATION FADER
- Modality
- Small Molecules
- Administration
- Oral, Topical
01
Overview
Miltefosine + imiquimod is a combination therapy consisting of oral miltefosine, an alkylphosphocholine antileishmanial agent, and topical imiquimod, an immune response modifier. Miltefosine acts primarily by disrupting cell membrane integrity and inducing apoptosis in Leishmania parasites. Imiquimod is a toll-like receptor 7 (TLR7) agonist that stimulates local immune responses, enhancing the host's ability to clear intracellular pathogens such as Leishmania species. This combination has been investigated for the treatment of cutaneous leishmaniasis, aiming to improve cure rates by combining direct antiparasitic activity with immunomodulation[1][2].
02
Targets
Leishmania cell membrane phospholipidsTLR7 (Toll-like receptor 7)
Beyond the preview
Go deeper on miltefosine + imiquimod.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on miltefosine + imiquimod.